title: [Orolingual angiooedema following intravenous thrombolysis].
authors.forename: Susana
authors.initials: S
authors.lastname: Arias-Rivas
authors.forename: María
authors.initials: M
authors.lastname: Pardo
authors.forename: Manuel
authors.initials: M
authors.lastname: Rodriguez-Yanez
authors.forename: Ana
authors.initials: A
authors.lastname: Lopez-Ferreiro
authors.forename: Miguel
authors.initials: M
authors.lastname: Blanco
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000369:Aged, 80 and over; D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001920:Bradykinin / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects; D002540:Cerebral Cortex / Q000098:blood supply / Q000503:physiopathology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy; D007262:Infusions, Intravenous; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D006633:Histamine Antagonists; D004656:Enalapril; D010959:Tissue Plasminogen Activator; D001920:Bradykinin